Long-term persistence of HIV with drug resistance after CD4 cell count-guided structured treatment interruption [5]

AIDS

Volumn 19, Issue 15, 2005, Pages 1713-1714

  Halfon, Philippe ^a   Pénaranda, Guillaume ^a   Khiri, Hacène ^a   Xerridat, Bernard ^b  

^a Hospital Ambroise Pare   (France)

^b Hopital Prive Clairval   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE;

ADULT; ANTIBIOTIC RESISTANCE; CASE REPORT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; MUTATION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD;

EID: 27144501594     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000184404.37282.8f     Document Type: Letter

References (8)

1. Halfon P, Durant J, Clevenbergh P, Carsenti H, Celis L, Khiri H, et al. Kinetics of disappearance of resistance mutations and reapperance of wilde-type during structured treatment interruptions. AIDS 2003; 17:1351-1361.
2. Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, et al. Development of HIV with drug resistance after CD4 cell count. Guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual nucleoside analogue treatment. Clin Infect Dis 2005; 40:728-734.
3. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 15:594-600.
4. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful anti-retroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
5. Florence E, Garcia F, Plana M, Fumero E, Castro P, Lopez A, et al. Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. Clin Infect Dis 2004; 39:569-574.
6. Torti C, Moretti F, Uccelli MC, Tirelli V, Quiros-Roldan E, Gargiulo F, Carosi G. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case. Med Sci Monit 2003; 9:CS16-CS19.
7. Tirado G, Jove G, Kumar R, Noel RJ, Reyes E, Sepulveda G, et al. Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female. AIDS Res Hum Retroviruses 2004; 20:684-686.
8. Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, et al., and the Swiss HIV Cohot Study. Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol 2003; 77:13146-13155.